Document 2797
 DOCN  M94A2797
 TI    Response to N-acetyl-L-cysteine on the CD4-CD8 system.
 DT    9412
 AU    Focaccia R; Cattapan A; Conceicao O; Buainain R; Salaroli A; Focaccia
       MT; Fac. Medicina Jundiai, Brazil.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):222 (abstract no. PB0319). Unique
       Identifier : AIDSLINE ICA10/94369778
 AB    We report the first results of a clinical trial conducted to test the
       response of CD4-CD8 lymphocyte system to the administration of
       N-Acetyl-L-Cysteine (NAC). HIV-positive patients bearing CD4 counts <
       500 cells/mm3 measured by flow cytometry were studied. Patients were
       divided in 2 groups that received doses every 12 Hs during 1 mo., 8
       cases Parenteral, 400 mg. 7 cases Oral, 600 mg. Five of the patients
       were being treated with AZT without significant change of CD4 counts.
       RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. Two of the 8 successful
       cases became serum p24 antigen negative. The 6 cases of the parenteral
       group ceased to develop opportunistic infections so far. No side effects
       were reported in both groups. CONCLUSION: NAC associated to antiviral
       therapy can be a powerful immunotherapy drug. Current research effort is
       aimed to determine the clinical meaning of CD4-CD8 enhancement and the
       determination of a suitable maintenance schedule.
 DE    Acetylcysteine/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/THERAPEUTIC  USE
       Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/*PHARMACOLOGY/
       THERAPEUTIC USE  Administration, Oral  Flow Cytometry  Human  HIV
       Infections/IMMUNOLOGY/*THERAPY  Injections  Leukocyte Count/*DRUG
       EFFECTS  T-Lymphocytes, Cytotoxic/*DRUG EFFECTS  Treatment Outcome  T4
       Lymphocytes/*DRUG EFFECTS  Zidovudine/THERAPEUTIC USE  CLINICAL TRIAL
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).